Eli Lilly $1 Bn Hyderabad Investment: Revanth Reddy Renews Push

Eli Lilly’s $1 Bn Hyderabad Investment Gets Fresh Push from Telangana CM

Eli Lilly’s $1 Bn Hyderabad Investment Gets Fresh Push from Telangana CM

Revanth Reddy also highlighted Hyderabad’s established pharmaceutical ecosystem, stating that the city accounted for 40% of India’s bulk drug production.

US pharmaceutical major Eli Lilly’s proposed $1 Bn investment in Hyderabad has received renewed attention after Telangana Chief Minister A Revanth Reddy reiterated the state’s commitment to attracting global pharmaceutical and life sciences companies.

Eli Lilly announced plans in October 2025 to establish a manufacturing and quality facility in Hyderabad as part of its $1 Bn commitment to expand its manufacturing and medicine supply capabilities in India.

The announcement followed a meeting between a company delegation led by global president Patrik Jonsson and Revanth Reddy, along with Telangana Industries Minister D Sridhar Babu.

The proposed facility is intended to strengthen the company’s manufacturing and supply network while supporting advanced technical capabilities and quality oversight.

Speaking at a recent event in Hyderabad, Revanth Reddy highlighted Telangana’s policies for attracting investment, saying that the state had taken steps to facilitate business operations through access to land, water, approvals and infrastructure, adding that the government would extend support to entrepreneurs.

The chief minister’s latest remarks have renewed the focus on Eli Lilly’s proposed $1 Bn Hyderabad investment.

However, no new investment agreement, project location, construction timeline or employment estimate was announced.

Revanth Reddy also highlighted Hyderabad’s established pharmaceutical ecosystem, stating that the city accounted for 40% of India’s bulk drug production.

He traced the sector’s development to the establishment of Indian Drugs and Pharmaceuticals Limited (IDPL) in the 1960s and pointed to research and development as a factor in the city’s international recognition.

The growing presence of global companies establishing Global Capability Centres has further contributed to Hyderabad’s business profile.

The state government has also outlined broader healthcare infrastructure investments. Revanth Reddy said Telangana was spending INR 12,000 Cr on hospital infrastructure, including Telangana Institute of Medical Sciences (TIMS) hospitals and the new Osmania General Hospital at Goshamahal.

He added that approximately INR 2,500 Cr was being spent annually through the Aarogyasri health scheme and the Chief Minister’s Relief Fund.

The chief minister also highlighted the potential use of health data to identify disease patterns across geographical areas and support more targeted public health interventions.

Eli Lilly’s investment is expected to strengthen the company’s manufacturing and medicine supply capabilities in India, further highlighting Hyderabad’s role in the pharmaceutical sector.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All

Welcome back.

Pick up where you left off on Digital Health News.

Sign in to DHN

For existing DHN and DHN Plus members.

or
Continue with Google
New to DHN?